[1]温慧军.糖皮质激素对重症肌无力患者血清肿瘤坏死因子及白介素-6水平的影响[J].卒中与神经疾病杂志,2017,24(04):332-334.[doi:10.3969/j.issn.1007-0478.2017.04.013]
　Wen Huijun..The effect of glucocorticoid on serum tumor necrosis factor and IL-6 in patients with myasthenia gravis[J].Stroke and Nervous Diseases,2017,24(04):332-334.[doi:10.3969/j.issn.1007-0478.2017.04.013]
点击复制

糖皮质激素对重症肌无力患者血清肿瘤坏死因子及白介素-6水平的影响()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第24卷
期数:
2017年04期
页码:
332-334
栏目:
论 著
出版日期:
2017-08-26

文章信息/Info

Title:
The effect of glucocorticoid on serum tumor necrosis factor and IL-6 in patients with myasthenia gravis
文章编号:
1007-0478(2017)04-0332-03
作者:
温慧军
721008 陕西省宝鸡市中心医院神经内科
Author(s):
Wen Huijun.
Department of Neurology,Baoji Central Hospital,Shanxi 721008
关键词:
重症肌无力 糖皮质激素 肿瘤坏死因子 白细胞介素-6
Keywords:
Myasthenia gravis Glucocorticoid Tumor necrosis factor Interleukin-6
分类号:
R746.1
DOI:
10.3969/j.issn.1007-0478.2017.04.013
摘要:
目的 探讨糖皮质激素(GC)对重症肌无力(MG)患者血清肿瘤坏死因子(TNF)及白细胞介素-6(IL-6)水平的影响。方法 选择48 例MG 患者(治疗组),采用GC治疗,疗程1个月,观察治疗前后患者血清TNF及IL-6的水平,并在治疗前与42例健康者(对照组)比较。结果 治疗组治疗前患者血清TNF、IL-6水平均明显高于对照组(P<0.05),经GC治疗1个月后治疗组患者血清TNF、IL-6 水平降低,与治疗前比较有明显差异(P<0.05)。结论 GC可能通过抑制MG患者体内TNF及IL-6的产生来调节患者的免疫功能。
Abstract:
ObjectiveTo analyse the effect of Glucocorticoid(GC)on serum tumor necrosis factor(TNF)and interleukin -6(IL-6)in the patients with myasthenia gravis(MG).Methods 48 MG patients(treatment group), which treated with GC for 1 months, were selected to observed the value in the serum of TNF and IL-6 before and after treatment, meanwhile, there were 42 healthy subjects(control group)chosen to be compared with treatment group before GC treatment to discover its therapeutic effect.Results Before the treatment carried out, the TNF and IL-6 serum of the treatment group were significantly higher than those of the control group, and the difference was statistically significant(P<0.05), after GC treatment of 1 months, the serum levels of TNF, IL-6 in the treatment group significantly reduced comparing with those of pretherapy, the difference was statistically significant(P<0.05).Conclusion The immune function of patients might be regulated from GC by inhibiting the production of TNF and IL-6 in patients with MG, and using the GC would have a great effect.

参考文献/References:

[1] Spring J,Spies M.Myasthenia gravis: options and timing of immunomodulatory treatment[J].BioDrugs,2001,15(3):173-183.
[2] Sathasivam Sivakumar.Steroids and immunosuppressant drugs in myasthenia gravis[J].Nat Clin Pract Neurol,2008,4(6):317-327.
[3] 中华医学会神经病学分会神经免疫学组.中国免疫学会神经免疫学分会.中国重症肌无力诊断和治疗指南[J].中华神经科杂志,2015,3(2):934.
[4] 李柱一,张魏.中国重症肌无力诊断和治疗专家共识[J].中国神经免疫学和神经病学杂志,2011,18(5):368-372.
[5] 许贤豪.肌无力—临床与基础[M].北京:中国协和医科大学出版社,2003:24.
[6] Saida K.Treatment of neuro-immunologic diseases by immunosuppressants[J].Nihon Rinsho,1994,52(11):3046-3052.
[7] Debono Miguel,Ghobadi Cyrus,Rostami-Hodjegan Amin,et al.Modified-release hydrocortisone to provide circadian cortisol profiles[J].J Clin Endocrinol Metab,2009,94(5):1548-1554.
[8] Utsugisawa Kimiaki,Nagane Yuriko.Therapeutic strategies against myasthenia gravis[J].Nihon Rinsho,2013,71(5):881-886.
[9] Anlar Banu,Senbil Nesrin,Köse Gül �瘙 塂 en,et al.Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years[J].Neuromuscul Disord,2005,15(5):355-357.
[10] Hirano.T-The biology of interleukin-6[J].Chem fmmunol,1992,9(4):153.
[11] Matusevicuis D,Navikas V,Palasik W,et al.Tumornecrosis factor-alpha,lymphotoxin,interleukin[J].-6,IL-10,IL-12 and perforin mRNA expression in monouclearcells in responsetoacety lcholinereceptoris augmented in myasthenia gravis〔J〕.Neuroimmunol,1996,71(1):191-193.
[12] 闫晓波,王维治,韩威.重症肌无力cICAM-1及TNF-α水平的检测[J].中国神经免疫学和神经病学杂志,2002,9(2):79-81.
[13] Deren H,Ritva PS.Tumo r necr osis factor-α polymorphism and secretion in myasthenia gravis[J].J Neuroimmunol,1999,94(8):165-171.
[14] 赖祥青,杨明山,徐金枝,等.重症肌无力患者免疫发病机制的研究[J].中国病理生理杂志,2001,17(7):662-664.

更新日期/Last Update: 2017-08-20